Oramed Pharmaceuticals (ORMP) Free Cash Flow (2010 - 2026)

Oramed Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at -$2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 17.09% year-over-year to -$2.9 million; the trailing twelve-month figure through Mar 2026 stood at -$8.6 million (up 18.35% YoY), and the FY2025 full-year result was -$9.2 million, down 8.59% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$2.9 million, down from -$468000.0 in the prior quarter.
• The five-year high for Free Cash Flow was $2.1 million in Q2 2024, with the low at -$9.2 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$3.5 million across 5 years, with a median of -$2.7 million in 2023.
• The largest YoY upside for Free Cash Flow was 178.22% in 2024 against a maximum downside of 878.79% in 2024.
• Oramed Pharmaceuticals' Free Cash Flow stood at -$8.4 million in 2022, then surged by 83.02% to -$1.4 million in 2023, then tumbled by 35.26% to -$1.9 million in 2024, then soared by 75.65% to -$468000.0 in 2025, then plunged by 523.93% to -$2.9 million in 2026.
• The last three Free Cash Flow figures came in at -$2.9 million (Q1 2026), -$468000.0 (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.